BRAF mutations in an Italian cohort of thyroid cancers
- 14 July 2004
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 61 (2) , 239-243
- https://doi.org/10.1111/j.1365-2265.2004.02089.x
Abstract
Objective Recently, a somatic point mutation of the BRAF gene (V599E) has been identified as the most common genetic event in papillary thyroid carcinoma (PTC) with a variable frequency (about 25–70%) in different series from USA, Japan, Portugal and Ukraine. design In the present study, the genetic analysis of BRAF in an Italian cohort of 65 thyroid tumours with corresponding normal tissues and 21 thyroid benign disorders is reported. methods For BRAF analysis, the somatic DNA was PCR amplified by means of specific intronic primers and PCR products were directly sequenced. Statistical analyses were obtained by means of Fisher's exact test. results All mutations detected involved a T > A transversion at 1796 (V599E) and were heterozygous. Overall, BRAFV599E mutation was found in 18/56 (32·1%) PTCs. According to the histological type of the tumour, the mutation was present in 38·3% of cases of conventional PTC (18/47), in 0/6 follicular variant of PTC, in 0/3 oncocytic variant of PTC. No BRAF mutations were detected either in five follicular carcinomas, or in four poorly differentiated or undifferentiated cancers or in benign thyroid disorders. No statistically significant correlation of BRAF mutation with patient age and gender, with multicentricity of the tumour, with the lymphocytic infiltration of the tissue, with the stage and with the recurrence rate, was found. BRAFV599E tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery. conclusions In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of 38·3% of BRAFV599E in the classical variant of PTC, confirming the key role of this mutation in promoting tumourigenesis.Keywords
This publication has 15 references indexed in Scilit:
- In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumoursThe Journal of Pathology, 2004
- BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup StudyJournal of Clinical Oncology, 2004
- BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary CarcinomasJournal of Clinical Endocrinology & Metabolism, 2003
- BRAF and KRAS mutations in stomach cancerOncogene, 2003
- BRAF mutations in papillary carcinomas of the thyroidOncogene, 2003
- Clinical Implication of Hot SpotBRAFMutation, V599E, in Papillary Thyroid CancersJournal of Clinical Endocrinology & Metabolism, 2003
- BRAF Mutation in Papillary Thyroid CarcinomaJNCI Journal of the National Cancer Institute, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Development of anticancer drugs targeting the MAP kinase pathwayOncogene, 2000
- Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivoNature Medicine, 1999